Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
14
BBNX Quote, Financials, Valuation and Earnings
Last price:
$12.51
Seasonality move
:
-41.61%
Day range:
$12.39 - $12.98
52-week range:
$8.89 - $32.71
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
5.50x
P/B ratio:
1.95x
Volume:
684.6K
Avg. volume:
1.2M
1-year change:
-36.56%
Market cap:
$560.5M
Revenue:
$100.3M
EPS (TTM):
-$1.68
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BBNX
Beta Bionics, Inc.
|
$31.1M | -$0.38 | 52.53% | -33.81% | $23.42 |
|
ABT
Abbott Laboratories
|
$11.8B | $1.49 | 6.14% | 54.88% | $133.39 |
|
ARAY
Accuray, Inc.
|
$100.9M | -$0.11 | -1.19% | -296.83% | $2.53 |
|
PODD
Insulet Corp.
|
$768.7M | $1.46 | 28.11% | 139.34% | $354.40 |
|
PSTV
Plus Therapeutics, Inc.
|
$1.2M | -$0.04 | 22.78% | -97.49% | $5.50 |
|
TNDM
Tandem Diabetes Care, Inc.
|
$277.2M | -$0.09 | 2.62% | -77.6% | $29.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BBNX
Beta Bionics, Inc.
|
$12.63 | $23.42 | $560.5M | -- | $0.00 | 0% | 5.50x |
|
ABT
Abbott Laboratories
|
$116.35 | $133.39 | $202.3B | 31.30x | $0.63 | 2.06% | 4.59x |
|
ARAY
Accuray, Inc.
|
$0.58 | $2.53 | $68.6M | 149.00x | $0.00 | 0% | 0.15x |
|
PODD
Insulet Corp.
|
$246.61 | $354.40 | $17.4B | 70.44x | $0.00 | 0% | 6.51x |
|
PSTV
Plus Therapeutics, Inc.
|
$0.30 | $5.50 | $41.6M | -- | $0.00 | 0% | 4.85x |
|
TNDM
Tandem Diabetes Care, Inc.
|
$25.30 | $29.50 | $1.7B | -- | $0.00 | 0% | 1.68x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BBNX
Beta Bionics, Inc.
|
2.48% | 5.653 | 0.54% | 7.65x |
|
ABT
Abbott Laboratories
|
21.33% | 0.218 | 6.97% | 1.05x |
|
ARAY
Accuray, Inc.
|
76.53% | 1.787 | 177.87% | 0.52x |
|
PODD
Insulet Corp.
|
39.8% | 1.567 | 5.01% | 1.82x |
|
PSTV
Plus Therapeutics, Inc.
|
0.41% | -3.087 | 0.02% | 1.22x |
|
TNDM
Tandem Diabetes Care, Inc.
|
74.33% | 0.412 | 30.15% | 1.92x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BBNX
Beta Bionics, Inc.
|
$18.9M | -$16.1M | -27.95% | -28.73% | -50.2% | -$10.5M |
|
ABT
Abbott Laboratories
|
$6.1B | $2.4B | 10.13% | 12.91% | 20.68% | $2.6B |
|
ARAY
Accuray, Inc.
|
$24.1M | -$5.5M | -14.23% | -60.6% | -5.37% | -$21.6M |
|
PODD
Insulet Corp.
|
$570.3M | $146.3M | 9.17% | 17.89% | 18.67% | $33.9M |
|
PSTV
Plus Therapeutics, Inc.
|
$1.3M | -$4.5M | -- | -- | -320.83% | -$2.6M |
|
TNDM
Tandem Diabetes Care, Inc.
|
$167.5M | $8.3M | -32.45% | -121.88% | 2.86% | $3.1M |
Beta Bionics, Inc. vs. Competitors
-
Which has Higher Returns BBNX or ABT?
Abbott Laboratories has a net margin of -41.92% compared to Beta Bionics, Inc.'s net margin of 15.71%. Beta Bionics, Inc.'s return on equity of -28.73% beat Abbott Laboratories's return on equity of 12.91%.
Company Gross Margin Earnings Per Share Invested Capital BBNXBeta Bionics, Inc.58.98% -$0.30 $294.9M ABTAbbott Laboratories53.5% $1.03 $66.9B -
What do Analysts Say About BBNX or ABT?
Beta Bionics, Inc. has a consensus price target of $23.42, signalling upside risk potential of 85.41%. On the other hand Abbott Laboratories has an analysts' consensus of $133.39 which suggests that it could grow by 14.65%. Given that Beta Bionics, Inc. has higher upside potential than Abbott Laboratories, analysts believe Beta Bionics, Inc. is more attractive than Abbott Laboratories.
Company Buy Ratings Hold Ratings Sell Ratings BBNXBeta Bionics, Inc.8 3 0 ABTAbbott Laboratories16 7 0 -
Is BBNX or ABT More Risky?
Beta Bionics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Abbott Laboratories has a beta of 0.741, suggesting its less volatile than the S&P 500 by 25.919%.
-
Which is a Better Dividend Stock BBNX or ABT?
Beta Bionics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Abbott Laboratories offers a yield of 2.06% to investors and pays a quarterly dividend of $0.63 per share. Beta Bionics, Inc. pays -- of its earnings as a dividend. Abbott Laboratories pays out 64.54% of its earnings as a dividend. Abbott Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BBNX or ABT?
Beta Bionics, Inc. quarterly revenues are $32.1M, which are smaller than Abbott Laboratories quarterly revenues of $11.5B. Beta Bionics, Inc.'s net income of -$13.5M is lower than Abbott Laboratories's net income of $1.8B. Notably, Beta Bionics, Inc.'s price-to-earnings ratio is -- while Abbott Laboratories's PE ratio is 31.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Beta Bionics, Inc. is 5.50x versus 4.59x for Abbott Laboratories. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BBNXBeta Bionics, Inc.5.50x -- $32.1M -$13.5M ABTAbbott Laboratories4.59x 31.30x $11.5B $1.8B
-
Which has Higher Returns BBNX or ARAY?
Accuray, Inc. has a net margin of -41.92% compared to Beta Bionics, Inc.'s net margin of -13.47%. Beta Bionics, Inc.'s return on equity of -28.73% beat Accuray, Inc.'s return on equity of -60.6%.
Company Gross Margin Earnings Per Share Invested Capital BBNXBeta Bionics, Inc.58.98% -$0.30 $294.9M ARAYAccuray, Inc.23.54% -$0.11 $227.6M -
What do Analysts Say About BBNX or ARAY?
Beta Bionics, Inc. has a consensus price target of $23.42, signalling upside risk potential of 85.41%. On the other hand Accuray, Inc. has an analysts' consensus of $2.53 which suggests that it could grow by 337.23%. Given that Accuray, Inc. has higher upside potential than Beta Bionics, Inc., analysts believe Accuray, Inc. is more attractive than Beta Bionics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BBNXBeta Bionics, Inc.8 3 0 ARAYAccuray, Inc.2 0 0 -
Is BBNX or ARAY More Risky?
Beta Bionics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Accuray, Inc. has a beta of 1.192, suggesting its more volatile than the S&P 500 by 19.162%.
-
Which is a Better Dividend Stock BBNX or ARAY?
Beta Bionics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Accuray, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Beta Bionics, Inc. pays -- of its earnings as a dividend. Accuray, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BBNX or ARAY?
Beta Bionics, Inc. quarterly revenues are $32.1M, which are smaller than Accuray, Inc. quarterly revenues of $102.2M. Beta Bionics, Inc.'s net income of -$13.5M is higher than Accuray, Inc.'s net income of -$13.8M. Notably, Beta Bionics, Inc.'s price-to-earnings ratio is -- while Accuray, Inc.'s PE ratio is 149.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Beta Bionics, Inc. is 5.50x versus 0.15x for Accuray, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BBNXBeta Bionics, Inc.5.50x -- $32.1M -$13.5M ARAYAccuray, Inc.0.15x 149.00x $102.2M -$13.8M
-
Which has Higher Returns BBNX or PODD?
Insulet Corp. has a net margin of -41.92% compared to Beta Bionics, Inc.'s net margin of 12.96%. Beta Bionics, Inc.'s return on equity of -28.73% beat Insulet Corp.'s return on equity of 17.89%.
Company Gross Margin Earnings Per Share Invested Capital BBNXBeta Bionics, Inc.58.98% -$0.30 $294.9M PODDInsulet Corp.72.76% $1.44 $2.5B -
What do Analysts Say About BBNX or PODD?
Beta Bionics, Inc. has a consensus price target of $23.42, signalling upside risk potential of 85.41%. On the other hand Insulet Corp. has an analysts' consensus of $354.40 which suggests that it could grow by 43.71%. Given that Beta Bionics, Inc. has higher upside potential than Insulet Corp., analysts believe Beta Bionics, Inc. is more attractive than Insulet Corp..
Company Buy Ratings Hold Ratings Sell Ratings BBNXBeta Bionics, Inc.8 3 0 PODDInsulet Corp.18 1 0 -
Is BBNX or PODD More Risky?
Beta Bionics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Insulet Corp. has a beta of 1.422, suggesting its more volatile than the S&P 500 by 42.204%.
-
Which is a Better Dividend Stock BBNX or PODD?
Beta Bionics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Beta Bionics, Inc. pays -- of its earnings as a dividend. Insulet Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BBNX or PODD?
Beta Bionics, Inc. quarterly revenues are $32.1M, which are smaller than Insulet Corp. quarterly revenues of $783.8M. Beta Bionics, Inc.'s net income of -$13.5M is lower than Insulet Corp.'s net income of $101.6M. Notably, Beta Bionics, Inc.'s price-to-earnings ratio is -- while Insulet Corp.'s PE ratio is 70.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Beta Bionics, Inc. is 5.50x versus 6.51x for Insulet Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BBNXBeta Bionics, Inc.5.50x -- $32.1M -$13.5M PODDInsulet Corp.6.51x 70.44x $783.8M $101.6M
-
Which has Higher Returns BBNX or PSTV?
Plus Therapeutics, Inc. has a net margin of -41.92% compared to Beta Bionics, Inc.'s net margin of -316.61%. Beta Bionics, Inc.'s return on equity of -28.73% beat Plus Therapeutics, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BBNXBeta Bionics, Inc.58.98% -$0.30 $294.9M PSTVPlus Therapeutics, Inc.93.84% -$0.04 $5.1M -
What do Analysts Say About BBNX or PSTV?
Beta Bionics, Inc. has a consensus price target of $23.42, signalling upside risk potential of 85.41%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 1716.98%. Given that Plus Therapeutics, Inc. has higher upside potential than Beta Bionics, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than Beta Bionics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BBNXBeta Bionics, Inc.8 3 0 PSTVPlus Therapeutics, Inc.4 0 0 -
Is BBNX or PSTV More Risky?
Beta Bionics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.788, suggesting its less volatile than the S&P 500 by 21.173%.
-
Which is a Better Dividend Stock BBNX or PSTV?
Beta Bionics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Beta Bionics, Inc. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BBNX or PSTV?
Beta Bionics, Inc. quarterly revenues are $32.1M, which are larger than Plus Therapeutics, Inc. quarterly revenues of $1.4M. Beta Bionics, Inc.'s net income of -$13.5M is lower than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, Beta Bionics, Inc.'s price-to-earnings ratio is -- while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Beta Bionics, Inc. is 5.50x versus 4.85x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BBNXBeta Bionics, Inc.5.50x -- $32.1M -$13.5M PSTVPlus Therapeutics, Inc.4.85x -- $1.4M -$4.4M
-
Which has Higher Returns BBNX or TNDM?
Tandem Diabetes Care, Inc. has a net margin of -41.92% compared to Beta Bionics, Inc.'s net margin of -0.2%. Beta Bionics, Inc.'s return on equity of -28.73% beat Tandem Diabetes Care, Inc.'s return on equity of -121.88%.
Company Gross Margin Earnings Per Share Invested Capital BBNXBeta Bionics, Inc.58.98% -$0.30 $294.9M TNDMTandem Diabetes Care, Inc.57.67% -$0.01 $604.5M -
What do Analysts Say About BBNX or TNDM?
Beta Bionics, Inc. has a consensus price target of $23.42, signalling upside risk potential of 85.41%. On the other hand Tandem Diabetes Care, Inc. has an analysts' consensus of $29.50 which suggests that it could grow by 16.6%. Given that Beta Bionics, Inc. has higher upside potential than Tandem Diabetes Care, Inc., analysts believe Beta Bionics, Inc. is more attractive than Tandem Diabetes Care, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BBNXBeta Bionics, Inc.8 3 0 TNDMTandem Diabetes Care, Inc.8 14 0 -
Is BBNX or TNDM More Risky?
Beta Bionics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Tandem Diabetes Care, Inc. has a beta of 1.626, suggesting its more volatile than the S&P 500 by 62.563%.
-
Which is a Better Dividend Stock BBNX or TNDM?
Beta Bionics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tandem Diabetes Care, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Beta Bionics, Inc. pays -- of its earnings as a dividend. Tandem Diabetes Care, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BBNX or TNDM?
Beta Bionics, Inc. quarterly revenues are $32.1M, which are smaller than Tandem Diabetes Care, Inc. quarterly revenues of $290.4M. Beta Bionics, Inc.'s net income of -$13.5M is lower than Tandem Diabetes Care, Inc.'s net income of -$589K. Notably, Beta Bionics, Inc.'s price-to-earnings ratio is -- while Tandem Diabetes Care, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Beta Bionics, Inc. is 5.50x versus 1.68x for Tandem Diabetes Care, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BBNXBeta Bionics, Inc.5.50x -- $32.1M -$13.5M TNDMTandem Diabetes Care, Inc.1.68x -- $290.4M -$589K
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
47
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
54
AAOI alert for Mar 2
Applied Optoelectronics, Inc. [AAOI] is up 21.71% over the past day.
Buy
90
BNAI alert for Mar 2
Brand Engagement Network, Inc. [BNAI] is up 2.44% over the past day.
Sell
36
WLDN alert for Mar 2
Willdan Group, Inc. [WLDN] is down 1.93% over the past day.
